These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 34069541)

  • 1. Next Step in Gene Delivery: Modern Approaches and Further Perspectives of AAV Tropism Modification.
    Korneyenkov MA; Zamyatnin AA
    Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34069541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer.
    Kwon I; Schaffer DV
    Pharm Res; 2008 Mar; 25(3):489-99. PubMed ID: 17763830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adeno-Associated Virus (AAV) Vectors: Rational Design Strategies for Capsid Engineering.
    Lee EJ; Guenther CM; Suh J
    Curr Opin Biomed Eng; 2018 Sep; 7():58-63. PubMed ID: 31106283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AAV Engineering for Improving Tropism to the Central Nervous System.
    Ghauri MS; Ou L
    Biology (Basel); 2023 Jan; 12(2):. PubMed ID: 36829465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Directed evolution of adeno-associated virus (AAV) as vector for muscle gene therapy.
    Yang L; Li J; Xiao X
    Methods Mol Biol; 2011; 709():127-39. PubMed ID: 21194025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AAV vectors: The Rubik's cube of human gene therapy.
    Pupo A; Fernández A; Low SH; François A; Suárez-Amarán L; Samulski RJ
    Mol Ther; 2022 Dec; 30(12):3515-3541. PubMed ID: 36203359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of gene transfer to the murine liver following intraperitoneal and intraportal delivery of hepatotropic AAV pseudo-serotypes.
    Dane AP; Wowro SJ; Cunningham SC; Alexander IE
    Gene Ther; 2013 Apr; 20(4):460-4. PubMed ID: 22895507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism.
    Wu P; Xiao W; Conlon T; Hughes J; Agbandje-McKenna M; Ferkol T; Flotte T; Muzyczka N
    J Virol; 2000 Sep; 74(18):8635-47. PubMed ID: 10954565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy.
    Grimm D; Kay MA
    Curr Gene Ther; 2003 Aug; 3(4):281-304. PubMed ID: 12871018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmable Assembly of Adeno-Associated Virus-Antibody Composites for Receptor-Mediated Gene Delivery.
    Zdechlik AC; He Y; Aird EJ; Gordon WR; Schmidt D
    Bioconjug Chem; 2020 Apr; 31(4):1093-1106. PubMed ID: 31809024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SUMOylation Targets Adeno-associated Virus Capsids but Mainly Restricts Transduction by Cellular Mechanisms.
    Chen Q; Njenga R; Leuchs B; Chiocca S; Kleinschmidt J; Müller M
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor targeting of adeno-associated virus vectors.
    Büning H; Ried MU; Perabo L; Gerner FM; Huttner NA; Enssle J; Hallek M
    Gene Ther; 2003 Jul; 10(14):1142-51. PubMed ID: 12833123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Codon-Optimization of Wild-Type Adeno-Associated Virus Capsid Sequences Enhances DNA Family Shuffling while Conserving Functionality.
    Cabanes-Creus M; Ginn SL; Amaya AK; Liao SHY; Westhaus A; Hallwirth CV; Wilmott P; Ward J; Dilworth KL; Santilli G; Rybicki A; Nakai H; Thrasher AJ; Filip AC; Alexander IE; Lisowski L
    Mol Ther Methods Clin Dev; 2019 Mar; 12():71-84. PubMed ID: 30534580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cryo-electron Microscopy Reconstruction and Stability Studies of the Wild Type and the R432A Variant of Adeno-associated Virus Type 2 Reveal that Capsid Structural Stability Is a Major Factor in Genome Packaging.
    Drouin LM; Lins B; Janssen M; Bennett A; Chipman P; McKenna R; Chen W; Muzyczka N; Cardone G; Baker TS; Agbandje-McKenna M
    J Virol; 2016 Oct; 90(19):8542-51. PubMed ID: 27440903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid evolution of blood-brain-barrier-penetrating AAV capsids by RNA-driven biopanning.
    Nonnenmacher M; Wang W; Child MA; Ren XQ; Huang C; Ren AZ; Tocci J; Chen Q; Bittner K; Tyson K; Pande N; Chung CH; Paul SM; Hou J
    Mol Ther Methods Clin Dev; 2021 Mar; 20():366-378. PubMed ID: 33553485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of Targeted Adeno-Associated Virus (AAV) Vectors for Human Gene Therapy.
    Liu Y; Siriwon N; Rohrs JA; Wang P
    Curr Pharm Des; 2015; 21(22):3248-56. PubMed ID: 26027561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adeno-associated virus serotypes: vector toolkit for human gene therapy.
    Wu Z; Asokan A; Samulski RJ
    Mol Ther; 2006 Sep; 14(3):316-27. PubMed ID: 16824801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fantastic AAV Gene Therapy Vectors and How to Find Them-Random Diversification, Rational Design and Machine Learning.
    Becker J; Fakhiri J; Grimm D
    Pathogens; 2022 Jul; 11(7):. PubMed ID: 35890005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adeno-associated viral vectors and their redirection to cell-type specific receptors.
    Michelfelder S; Trepel M
    Adv Genet; 2009; 67():29-60. PubMed ID: 19914449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical modification of the adeno-associated virus capsid to improve gene delivery.
    Mével M; Bouzelha M; Leray A; Pacouret S; Guilbaud M; Penaud-Budloo M; Alvarez-Dorta D; Dubreil L; Gouin SG; Combal JP; Hommel M; Gonzalez-Aseguinolaza G; Blouin V; Moullier P; Adjali O; Deniaud D; Ayuso E
    Chem Sci; 2019 Dec; 11(4):1122-1131. PubMed ID: 34084369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.